Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck 4Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Merck 4Q Results

Pharmaceutical sales were $14.8 billion, up 6% in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Merck

Image: Merck

Merck

4Q Revenues: $16.4 billion +5%

4Q Earnings: $2.96 billion -21%

FY Revenues: $65.0 billion +1%

FY Earnings: $18.3 billion +7%

Comments: Pharmaceutical sales were $14.8 billion, up 6%. The increase was primarily driven by growth in oncology as well as cardiometabolic and respiratory, partially offset by a decline in vaccines.

KEYTRUDA sales were up 7% in the quarter to $8.3 billion. GARDASIL/GARDASIL 9 sales were down 34%, primarily due to lower demand in China. PROQUAD, M-M-R II and VARIVAX sales were $619 million, up 4%. JANUVIA/JANUMET sales were up 3% to $501 million. BRIDION sales were $499 million, up 11%. WINREVAIR sales were up 133% to $467 million Growth primarily reflects continued uptake in the U.S. and early launch uptake in certain international markets. Lynparza sales were up 7% to $389 million.

Earnings in the quarter include charges related to an agreement with Dr. Falk Pharma GmbH under which the Merck secured global rights to MK-8690, and licensing agreements with LaNova Medicines Ltd. (acquired by Sino Pharmaceutical Limited) and Hansoh Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics